GeneDx (NASDAQ:WGS) Rating Lowered to Strong Sell at Zacks Research

GeneDx (NASDAQ:WGS) was downgraded by analysts at Zacks Research from a “hold” rating to a “strong sell” rating in a research note issued on Monday,Zacks.com reports.

Several other equities analysts also recently commented on the stock. BTIG Research decreased their price target on shares of GeneDx from $170.00 to $90.00 and set a “buy” rating on the stock in a research note on Tuesday, May 5th. Piper Sandler reissued an “overweight” rating and issued a $63.00 price objective (up from $50.00) on shares of GeneDx in a report on Tuesday, June 23rd. Canaccord Genuity Group set a $75.00 target price on shares of GeneDx and gave the stock a “buy” rating in a research report on Tuesday, May 5th. Weiss Ratings cut shares of GeneDx from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday, June 1st. Finally, Wall Street Zen downgraded shares of GeneDx from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Six research analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company. Based on data from MarketBeat, GeneDx has a consensus rating of “Moderate Buy” and a consensus price target of $87.43.

GeneDx Price Performance

Shares of NASDAQ WGS opened at $68.65 on Monday. The firm has a market cap of $2.04 billion, a P/E ratio of -25.62 and a beta of 1.96. The business’s 50 day moving average is $54.39 and its 200-day moving average is $81.24. The company has a current ratio of 3.09, a quick ratio of 2.95 and a debt-to-equity ratio of 0.38. GeneDx has a 1-year low of $32.21 and a 1-year high of $170.87.

GeneDx (NASDAQ:WGS) last issued its quarterly earnings data on Monday, May 4th. The company reported ($0.28) EPS for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.22). GeneDx had a negative net margin of 17.58% and a positive return on equity of 9.15%. The firm had revenue of $102.25 million during the quarter, compared to analyst estimates of $112.46 million. During the same period in the prior year, the company earned ($0.23) earnings per share. Equities research analysts predict that GeneDx will post -1 earnings per share for the current year.

Insider Buying and Selling

In other news, Director Casdin Capital, Llc acquired 185,000 shares of the stock in a transaction on Tuesday, May 19th. The stock was acquired at an average cost of $42.60 per share, for a total transaction of $7,881,000.00. Following the completion of the transaction, the director directly owned 3,367,164 shares in the company, valued at approximately $143,441,186.40. This trade represents a 5.81% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Keith A. Meister bought 533,758 shares of the business’s stock in a transaction on Thursday, May 7th. The shares were acquired at an average price of $37.86 per share, with a total value of $20,208,077.88. Following the completion of the purchase, the director directly owned 3,761,908 shares of the company’s stock, valued at approximately $142,425,836.88. The trade was a 16.53% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Over the last three months, insiders purchased 2,256,420 shares of company stock worth $93,144,340 and sold 21,699 shares worth $1,295,646. Company insiders own 25.17% of the company’s stock.

Institutional Trading of GeneDx

Several large investors have recently bought and sold shares of the business. Kestra Advisory Services LLC acquired a new stake in shares of GeneDx in the 4th quarter valued at approximately $27,000. Ramirez Asset Management Inc. acquired a new position in GeneDx during the 4th quarter worth approximately $33,000. Greenline Wealth Management LLC bought a new position in GeneDx in the 4th quarter valued at approximately $33,000. Bank Julius Baer & Co. Ltd Zurich bought a new position in GeneDx in the 4th quarter valued at approximately $35,000. Finally, Quarry LP boosted its position in GeneDx by 248.8% in the third quarter. Quarry LP now owns 293 shares of the company’s stock valued at $32,000 after buying an additional 209 shares in the last quarter. 61.72% of the stock is owned by institutional investors and hedge funds.

GeneDx News Summary

Here are the key news stories impacting GeneDx this week:

• Positive Sentiment: No clearly positive company-specific news was reported in the latest articles.
• Neutral Sentiment: Several law firms, including Rosen, Faruqi & Faruqi, Robbins Geller, Kessler Topaz, and others, reminded investors of the August 3, 2026 deadline to seek lead-plaintiff status in the existing class action lawsuit against GeneDx. Article Title
• Neutral Sentiment: Hagens Berman said it is investigating claims in the securities case, but this largely reiterates the ongoing lawsuit rather than adding new operational developments. Article Title
• Negative Sentiment: Zacks Research downgraded GeneDx from hold to strong sell, reinforcing bearish sentiment around the shares. Article Title
• Negative Sentiment: The repeated class-action announcements may weigh on the stock by highlighting potential legal liability, investor-loss claims, and uncertainty around prior disclosure practices. Article Title

About GeneDx

GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx’s laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.

Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.